Evaluation of the effect of cannabidiol treatment on [ ¹⁸ F]FDG and [ ¹¹ C]PK11195 uptake in an animal model for Alzheimer's disease

Abstract

Background: Cannabidiol (CBD) has well‐described anti‐inflammatory and neuroprotective properties. Emerging preclinical research has explored the potential of this cannabinoid as a therapeutic agent to delay or prevent the onset of symptoms and pathophysiological features of neurodegenerative processes, such as Alzheimer's disease (AD).